Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Ani Pharmaceuticals Inc (ANIP) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Ani Pharmaceuticals Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1023024.
Total stock buying since 2015: $2,334,855.
Total stock sales since 2015: $199,357,841.
Total stock option exercises since 2015: $8,962,431.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 430,061 | $37,446,217 | 50,300 | $2,333,947 |
| 2024 | 0 | $0 | 569,517 | $36,033,709 | 42,550 | $1,538,726 |
| 2023 | 0 | $0 | 803,476 | $46,079,827 | 30,535 | $961,359 |
| 2022 | 32,224 | $890,381 | 218,066 | $8,373,071 | 0 | $0 |
| 2021 | 10,572 | $406,621 | 0 | $0 | 0 | $0 |
| 2020 | 20,000 | $662,880 | 0 | $0 | 0 | $0 |
| 2019 | 3,945 | $272,598 | 186,954 | $12,880,939 | 14,005 | $417,593 |
| 2018 | 0 | $0 | 331,994 | $20,658,595 | 107,148 | $1,822,073 |
| 2016 | 0 | $0 | 49,955 | $3,346,573 | 75,082 | $1,022,441 |
| 2015 | 2,500 | $102,375 | 548,500 | $34,538,910 | 68,143 | $866,292 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-09 | 0 | $0 | 7,292 | $692,302 | 0 | $0 |
| 2025-08 | 0 | $0 | 404,738 | $35,643,180 | 50,000 | $2,324,500 |
| 2025-07 | 0 | $0 | 400 | $25,952 | 0 | $0 |
| 2025-05 | 0 | $0 | 5,981 | $373,382 | 0 | $0 |
| 2025-04 | 0 | $0 | 400 | $27,583 | 0 | $0 |
| 2025-03 | 0 | $0 | 8,650 | $530,602 | 300 | $9,447 |
| 2025-02 | 0 | $0 | 2,200 | $131,648 | 0 | $0 |
| 2025-01 | 0 | $0 | 400 | $21,568 | 0 | $0 |
| 2024-12 | 0 | $0 | 8,750 | $492,485 | 0 | $0 |
| 2024-11 | 0 | $0 | 40,231 | $2,336,473 | 30,000 | $870,000 |
| 2024-10 | 0 | $0 | 250 | $14,297 | 0 | $0 |
| 2024-09 | 0 | $0 | 250 | $14,205 | 0 | $0 |
| 2024-08 | 0 | $0 | 250 | $14,905 | 0 | $0 |
| 2024-07 | 0 | $0 | 70,250 | $4,466,685 | 0 | $0 |
| 2024-06 | 0 | $0 | 78,235 | $4,817,706 | 12,550 | $668,726 |
| 2024-05 | 0 | $0 | 90,919 | $5,887,789 | 0 | $0 |
| 2024-04 | 0 | $0 | 70,250 | $4,635,263 | 0 | $0 |
| 2024-03 | 0 | $0 | 159,632 | $10,539,014 | 0 | $0 |
| 2024-02 | 0 | $0 | 250 | $14,010 | 0 | $0 |
| 2024-01 | 0 | $0 | 50,250 | $2,800,877 | 0 | $0 |
| 2023-12 | 0 | $0 | 50,250 | $2,639,551 | 0 | $0 |
| 2023-11 | 0 | $0 | 54,812 | $2,879,578 | 0 | $0 |
| 2023-10 | 0 | $0 | 70,000 | $4,022,502 | 0 | $0 |
| 2023-09 | 0 | $0 | 70,000 | $4,384,616 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-09-03 | Pera Antonio R | Sale | 7,292 | 94.94 | 692,302 |
| 2025-08-25 | Leonard Matthew J (Director) | Sale | 2,528 | 90.62 | 229,087 |
| 2025-08-22 | Davis Krista (SVP, CHIEF HR OFFICER) | Sale | 1,763 | 91.10 | 160,609 |
| 2025-08-21 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 52,988 | 90.44 | 4,792,234 |
| 2025-08-20 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 47,012 | 90.27 | 4,243,773 |
| 2025-08-20 | Pera Antonio R | Sale | 5,421 | 89.73 | 486,426 |
| 2025-08-18 | Thoma Jeanne | Sale | 21,540 | 89.31 | 1,923,845 |
| 2025-08-18 | Leonard Matthew J (Director) | Sale | 6,937 | 88.17 | 611,635 |
| 2025-08-15 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 86.97 | 1,739,400 |
| 2025-08-15 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 52,990 | 87.15 | 4,618,078 |
| 2025-08-15 | Walsh Patrick D | Sale | 9,000 | 89.05 | 801,450 |
| 2025-08-14 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 47,010 | 89.48 | 4,206,454 |
| 2025-08-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 400 | 88.87 | 35,548 |
| 2025-08-12 | Gutwerg Ori (SVP, GENERICS) | Sale | 5,873 | 86.53 | 508,190 |
| 2025-08-12 | Lalwani Nikhil (PRESIDENT & CEO) | Sale | 56,960 | 85.93 | 4,894,572 |
| 2025-08-12 | Carey Stephen P. (SVP & CFO) | Sale | 50,000 | 86.07 | 4,303,500 |
| 2025-08-12 | Carey Stephen P. (SVP & CFO) | Option Ex | 50,000 | 46.49 | 2,324,500 |
| 2025-08-12 | Rowland Thomas Andrew (SVP, HEAD - ESTABLISHED BRANDS) | Sale | 4,975 | 85.71 | 426,407 |
| 2025-08-12 | Haughey Thomas | Sale | 19,341 | 85.93 | 1,661,972 |
| 2025-07-14 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 400 | 64.88 | 25,952 |
| 2025-05-15 | Gutwerg Ori (SVP, GENERICS) | Sale | 881 | 60.07 | 52,921 |
| 2025-05-14 | Mutz Christopher (HEAD OF RARE DISEASE) | Sale | 4,000 | 60.45 | 241,800 |
| 2025-05-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 400 | 62.20 | 24,880 |
| 2025-05-09 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 700 | 76.83 | 53,781 |
| 2025-04-14 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 400 | 68.96 | 27,583 |
| 2025-03-19 | Davis Krista (SVP, CHIEF HR OFFICER) | Sale | 1,866 | 65.00 | 121,290 |
| 2025-03-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 400 | 63.33 | 25,332 |
| 2025-03-07 | Davis Krista (SVP, CHIEF HR OFFICER) | Sale | 1,000 | 60.86 | 60,860 |
| 2025-03-05 | Gutwerg Ori (SVP, GENERICS) | Sale | 5,384 | 60.02 | 323,120 |
| 2025-03-05 | Gutwerg Ori (SVP, GENERICS) | Option Ex | 300 | 31.49 | 9,447 |
| 2025-02-21 | Davis Krista (SVP, CHIEF HR OFFICER) | Sale | 1,000 | 60.20 | 60,200 |
| 2025-02-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 800 | 59.54 | 47,632 |
| 2025-01-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 400 | 53.92 | 21,568 |
| 2024-12-17 | Carey Stephen P. (SVP & CFO) | Sale | 7,500 | 55.79 | 418,425 |
| 2024-12-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 56.24 | 14,060 |
| 2024-12-11 | Davis Krista (SVP, CHIEF HR OFFICER) | Sale | 1,000 | 60.00 | 60,000 |
| 2024-11-26 | Lalwani Nikhil (PRESIDENT & CEO) | Sale | 33,481 | 58.12 | 1,946,083 |
| 2024-11-26 | Lalwani Nikhil (PRESIDENT & CEO) | Option Ex | 30,000 | 29.00 | 870,000 |
| 2024-11-15 | Mutz Christopher (HEAD OF RARE DISEASE) | Sale | 6,500 | 57.70 | 375,050 |
| 2024-11-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 61.36 | 15,340 |
| 2024-10-14 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 57.19 | 14,297 |
| 2024-09-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 56.82 | 14,205 |
| 2024-08-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 59.62 | 14,905 |
| 2024-07-18 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 2,743 | 62.00 | 170,066 |
| 2024-07-17 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 14,257 | 63.16 | 900,472 |
| 2024-07-16 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 22,000 | 64.27 | 1,413,940 |
| 2024-07-15 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 11,000 | 63.38 | 697,180 |
| 2024-07-12 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 64.91 | 16,227 |
| 2024-07-01 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 63.44 | 1,268,800 |
| 2024-06-21 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 20,000 | 58.90 | 1,178,000 |
| 2024-06-20 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 11,447 | 59.86 | 685,217 |
| 2024-06-18 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 10,607 | 60.76 | 644,481 |
| 2024-06-17 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 7,946 | 61.41 | 487,963 |
| 2024-06-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 63.80 | 15,950 |
| 2024-06-07 | Marken James G. (SVP OPS & PROD DEV) | Option Ex | 12,550 | 53.28 | 668,726 |
| 2024-06-05 | Gutwerg Ori (SVP, GENERICS) | Sale | 2,985 | 67.00 | 199,995 |
| 2024-06-04 | Carey Stephen P. (SVP & CFO) | Sale | 5,000 | 63.58 | 317,900 |
| 2024-06-03 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 64.41 | 1,288,200 |
| 2024-05-21 | Mutz Christopher (HEAD OF RARE DISEASE) | Sale | 2,000 | 61.61 | 123,220 |
| 2024-05-20 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 12,855 | 61.81 | 794,567 |
| 2024-05-17 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 5,836 | 62.09 | 362,357 |
| 2024-05-16 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 16,459 | 63.84 | 1,050,742 |
| 2024-05-16 | Tannenbaum Renee P | Sale | 2,000 | 63.87 | 127,740 |
| 2024-05-15 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 14,850 | 65.86 | 978,021 |
| 2024-05-14 | Lalwani Nikhil (PRESIDENT & CEO) | Sale | 16,669 | 66.10 | 1,101,820 |
| 2024-05-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 67.69 | 16,922 |
| 2024-05-01 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 66.62 | 1,332,400 |
| 2024-04-19 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 16,809 | 65.17 | 1,095,442 |
| 2024-04-18 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 10,423 | 64.98 | 677,286 |
| 2024-04-17 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 9,520 | 65.40 | 622,608 |
| 2024-04-16 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 5,834 | 66.20 | 386,210 |
| 2024-04-15 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 7,414 | 66.33 | 491,770 |
| 2024-04-12 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 67.79 | 16,947 |
| 2024-04-01 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 67.25 | 1,345,000 |
| 2024-03-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 66.54 | 16,635 |
| 2024-03-11 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 65.81 | 1,316,200 |
| 2024-03-11 | Carey Stephen P. (SVP & CFO) | Sale | 7,787 | 65.55 | 510,437 |
| 2024-03-08 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 10,000 | 67.17 | 671,700 |
| 2024-03-08 | Lalwani Nikhil (PRESIDENT & CEO) | Sale | 16,292 | 67.13 | 1,093,681 |
| 2024-03-07 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 15,085 | 66.35 | 1,000,889 |
| 2024-03-07 | Marken James G. (SVP OPS & PROD DEV) | Sale | 24,338 | 66.37 | 1,615,313 |
| 2024-03-06 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 14,822 | 65.47 | 970,396 |
| 2024-03-06 | Lalwani Nikhil (PRESIDENT & CEO) | Sale | 28,965 | 65.52 | 1,897,786 |
| 2024-03-05 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 10,093 | 65.35 | 659,577 |
| 2024-03-05 | Mutz Christopher (HEAD OF RARE DISEASE) | Sale | 5,000 | 66.00 | 330,000 |
| 2024-03-04 | Pera Antonio R | Sale | 7,000 | 65.20 | 456,400 |
| 2024-02-13 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 56.04 | 14,010 |
| 2024-01-23 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 15,000 | 56.44 | 846,600 |
| 2024-01-22 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 5,692 | 55.95 | 318,467 |
| 2024-01-19 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 4,524 | 55.57 | 251,398 |
| 2024-01-18 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 9,784 | 55.30 | 541,055 |
| 2024-01-17 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 10,000 | 55.11 | 551,100 |
| 2024-01-16 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 5,000 | 55.63 | 278,150 |
| 2024-01-12 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 56.43 | 14,107 |
| 2023-12-19 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 25,000 | 52.65 | 1,316,250 |
| 2023-12-18 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 13,026 | 52.44 | 683,083 |
| 2023-12-15 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 11,974 | 52.44 | 627,916 |
| 2023-12-11 | Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) | Sale | 250 | 49.21 | 12,302 |
| 2023-11-17 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 13,000 | 51.00 | 663,000 |
| 2023-11-16 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 6,448 | 51.66 | 333,103 |
| 2023-11-15 | Davis Krista (SVP, CHIEF HR OFFICER) | Sale | 2,622 | 53.81 | 141,089 |
| 2023-11-15 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 7,647 | 53.64 | 410,185 |
| 2023-11-14 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 22,095 | 53.17 | 1,174,791 |
| 2023-11-10 | Mutz Christopher (HEAD OF RARE DISEASE) | Sale | 3,000 | 52.47 | 157,410 |
| 2023-10-19 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 10,000 | 57.06 | 570,600 |
| 2023-10-18 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 6,242 | 57.78 | 360,662 |
| 2023-10-17 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 8,758 | 58.53 | 512,605 |
| 2023-10-16 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 13,063 | 58.31 | 761,703 |
| 2023-10-13 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 11,937 | 57.58 | 687,332 |
| 2023-10-02 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 56.48 | 1,129,600 |
| 2023-09-19 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 25,333 | 61.23 | 1,551,139 |
| 2023-09-18 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 8,425 | 61.64 | 519,317 |
| 2023-09-15 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 16,242 | 62.81 | 1,020,160 |
| 2023-09-01 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 64.70 | 1,294,000 |
| 2023-08-29 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 25,000 | 63.37 | 1,584,250 |
| 2023-08-28 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 25,000 | 63.06 | 1,576,500 |
| 2023-08-23 | Gutwerg Ori (SVP, GENERICS) | Sale | 15,561 | 62.39 | 970,850 |
| 2023-08-23 | Gutwerg Ori (SVP, GENERICS) | Option Ex | 13,502 | 31.49 | 425,177 |
| 2023-08-23 | Marken James G. (SVP OPS & PROD DEV) | Sale | 3,932 | 63.00 | 247,716 |
| 2023-08-23 | Marken James G. (SVP OPS & PROD DEV) | Option Ex | 5,417 | 36.80 | 199,318 |
| 2023-08-16 | Brown Robert E. Jr | Sale | 200,000 | 58.50 | 11,700,000 |
| 2023-08-15 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 22,110 | 61.60 | 1,361,976 |
| 2023-08-15 | Lalwani Nikhil (PRESIDENT & CEO) | Sale | 11,616 | 61.13 | 710,086 |
| 2023-08-15 | Lalwani Nikhil (PRESIDENT & CEO) | Option Ex | 11,616 | 29.00 | 336,864 |
| 2023-08-14 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 27,890 | 61.15 | 1,705,473 |
| 2023-08-14 | Pera Antonio R | Sale | 3,000 | 60.37 | 181,110 |
| 2023-08-14 | Carey Stephen P. (SVP & CFO) | Sale | 17,639 | 61.37 | 1,082,505 |
| 2023-08-11 | Lalwani Nikhil (PRESIDENT & CEO) | Sale | 56,666 | 57.75 | 3,272,461 |
| 2023-08-01 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 51.06 | 1,021,200 |
| 2023-07-21 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 11,500 | 52.56 | 604,440 |
| 2023-07-20 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 6,000 | 51.52 | 309,120 |
| 2023-07-19 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 5,969 | 51.48 | 307,284 |
| 2023-07-18 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 6,700 | 51.84 | 347,328 |
| 2023-07-17 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 9,831 | 51.06 | 501,970 |
| 2023-07-14 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 10,000 | 50.43 | 504,300 |
| 2023-07-03 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 53.43 | 1,068,600 |
| 2023-06-22 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Sale | 20,000 | 51.32 | 1,026,400 |
| 2023-06-22 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 13,500 | 51.38 | 693,630 |
| 2023-06-21 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 11,843 | 51.95 | 615,243 |
| 2023-06-20 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Sale | 14,657 | 51.93 | 761,138 |
| 2022-12-01 | Brown Robert E. Jr | Sale | 200,000 | 38.50 | 7,700,000 |
| 2022-08-15 | Marken James G. (SVP OPS & PROD DEV) | Sale | 5,172 | 37.79 | 195,465 |
| 2022-08-12 | Marken James G. (SVP OPS & PROD DEV) | Sale | 12,894 | 37.04 | 477,606 |
| 2022-03-21 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Buy | 5,000 | 27.87 | 139,345 |
| 2022-03-21 | Lalwani Nikhil (PRESIDENT & CEO) | Buy | 7,224 | 27.68 | 199,996 |
| 2022-03-21 | Walsh Patrick D | Buy | 5,000 | 27.76 | 138,795 |
| 2022-03-18 | Gassert Chad (SVP - CORP. DEV. & STRATEGY) | Buy | 5,000 | 27.15 | 135,745 |
| 2022-03-17 | Shanmugam Muthusamy (HEAD OF R&D, COO-NOVITIUM OPS) | Buy | 10,000 | 27.65 | 276,500 |
| 2021-12-20 | Thoma Jeanne | Buy | 1,072 | 46.47 | 49,820 |
| 2021-12-07 | Pera Antonio R | Buy | 3,000 | 42.27 | 126,795 |
| 2021-12-06 | Haughey Thomas | Buy | 2,500 | 39.38 | 98,450 |
| 2021-03-15 | Walsh Patrick D | Buy | 4,000 | 32.89 | 131,556 |
| 2020-11-09 | Walsh Patrick D | Buy | 5,000 | 25.96 | 129,800 |
| 2020-08-10 | Walsh Patrick D (CHAIRMAN, INTERIM PRES. & CEO) | Buy | 10,000 | 30.76 | 307,570 |
| 2020-03-04 | Haughey Thomas | Buy | 3,000 | 45.05 | 135,150 |
| 2020-03-03 | Haughey Thomas | Buy | 2,000 | 45.18 | 90,360 |
| 2019-08-20 | Brown Robert E. Jr | Sale | 5,512 | 68.18 | 375,808 |
| 2019-08-19 | Brown Robert E. Jr | Sale | 2,067 | 68.30 | 141,176 |
| 2019-08-16 | Brown Robert E. Jr | Sale | 26,349 | 68.09 | 1,794,103 |
| 2019-08-15 | Brown Robert E. Jr | Sale | 9,315 | 69.34 | 645,902 |
| 2019-08-14 | Brown Robert E. Jr | Sale | 26,360 | 69.89 | 1,842,300 |
| 2019-08-13 | Brown Robert E. Jr | Sale | 20,821 | 71.77 | 1,494,323 |
| 2019-08-12 | Brown Robert E. Jr | Sale | 21,016 | 71.45 | 1,501,593 |
| 2019-08-09 | Brown Robert E. Jr | Sale | 19,860 | 71.70 | 1,423,962 |
| 2019-05-24 | Nash David | Buy | 1,445 | 68.76 | 99,358 |
| 2019-05-17 | Marken James G. (SVP Ops & Prod Dev) | Sale | 8,907 | 70.67 | 629,457 |
| 2019-05-16 | Brown Robert E. Jr | Option Ex | 2,209 | 19.68 | 43,473 |
| 2019-05-15 | Haughey Thomas | Buy | 2,500 | 69.30 | 173,240 |
| 2019-05-14 | Marken James G. (SVP Ops & Prod Dev) | Sale | 4,917 | 70.31 | 345,714 |
| 2019-05-13 | Schrepfer Robert W (SVP - New Bus Dev & Spec Sales) | Sale | 2,409 | 71.13 | 171,352 |
| 2019-03-19 | Przybyl Arthur (President and CEO) | Sale | 2,823 | 63.51 | 179,288 |
| 2019-03-18 | Przybyl Arthur (President and CEO) | Sale | 24,802 | 63.53 | 1,575,671 |
| 2019-03-13 | Schrepfer Robert W (SVP - New Bus Dev & Spec Sales) | Sale | 4,651 | 64.43 | 299,645 |
| 2019-03-13 | Schrepfer Robert W (SVP - New Bus Dev & Spec Sales) | Option Ex | 4,651 | 33.00 | 153,483 |
| 2019-03-12 | Schrepfer Robert W (SVP - New Bus Dev & Spec Sales) | Sale | 7,145 | 64.47 | 460,645 |
| 2019-03-12 | Schrepfer Robert W (SVP - New Bus Dev & Spec Sales) | Option Ex | 7,145 | 30.88 | 220,637 |
| 2018-09-11 | Schrepfer Robert W (SVP - New Bus Dev & Spec Sales) | Option Ex | 28,688 | 6.60 | 189,340 |
| 2018-05-16 | Marshbanks Tracy | Sale | 25,706 | 62.40 | 1,604,054 |
| 2018-05-15 | Marshbanks Tracy | Sale | 7,024 | 62.05 | 435,839 |
| 2018-05-14 | Marshbanks Tracy | Sale | 5,506 | 62.35 | 343,299 |
| 2018-05-10 | Marshbanks Tracy | Sale | 41,914 | 62.09 | 2,602,230 |
| 2018-05-09 | Marshbanks Tracy | Sale | 20,517 | 62.05 | 1,273,079 |
| 2018-04-18 | Marshbanks Tracy | Sale | 33,200 | 62.09 | 2,061,388 |
| 2018-03-20 | Holubow Fred | Option Ex | 2,000 | .00 | 0 |
| 2018-03-19 | Raynor Daniel | Sale | 5,313 | 60.62 | 322,074 |
| 2018-03-15 | Raynor Daniel | Sale | 1,902 | 61.50 | 116,973 |
| 2018-03-14 | Marshbanks Tracy | Sale | 1,912 | 63.10 | 120,647 |
| 2018-03-14 | Przybyl Arthur (President and CEO) | Sale | 10,000 | 62.03 | 620,300 |
| 2018-03-14 | Raynor Daniel | Sale | 1,919 | 62.02 | 119,016 |
| 2018-03-13 | Przybyl Arthur (President and CEO) | Sale | 30,000 | 62.08 | 1,862,250 |
| 2018-03-13 | Raynor Daniel | Sale | 18,117 | 62.20 | 1,126,877 |
| 2018-03-12 | Marshbanks Tracy | Sale | 12,269 | 63.03 | 773,315 |
| 2018-03-12 | Przybyl Arthur (President and CEO) | Option Ex | 15,723 | 6.36 | 99,998 |
| 2018-03-12 | Raynor Daniel | Sale | 7,928 | 62.88 | 498,512 |
| 2018-03-09 | Marshbanks Tracy | Sale | 36,561 | 63.01 | 2,303,708 |
| 2018-03-08 | Marshbanks Tracy | Sale | 15,391 | 63.08 | 970,864 |
| 2018-03-05 | Marken James G. (SVP Ops & Prod Dev) | Sale | 4,177 | 61.92 | 258,639 |
| 2018-03-05 | Marken James G. (SVP Ops & Prod Dev) | Option Ex | 18,001 | 19.68 | 354,259 |
| 2018-03-01 | Schrepfer Robert W (SVP - New Bus Dev & Spec Sales) | Sale | 28,652 | 61.82 | 1,771,352 |
| 2018-03-01 | Schrepfer Robert W (SVP - New Bus Dev & Spec Sales) | Option Ex | 18,750 | 28.76 | 539,250 |
| 2018-03-01 | Przybyl Arthur (President and CEO) | Sale | 23,986 | 61.46 | 1,474,179 |
| 2018-03-01 | Przybyl Arthur (President and CEO) | Option Ex | 23,986 | 26.65 | 639,226 |
| 2016-11-15 | Brown Robert E. Jr | Option Ex | 5,458 | 19.68 | 107,413 |
| 2016-08-22 | Przybyl Arthur (President and CEO) | Sale | 37,455 | 66.97 | 2,508,361 |
| 2016-08-22 | Przybyl Arthur (President and CEO) | Option Ex | 53,178 | 15.24 | 810,432 |
| 2016-08-08 | Schrepfer Robert W (VP Bus Dev & Con Mfg) | Sale | 12,500 | 67.06 | 838,212 |
| 2016-01-08 | Przybyl Arthur (President and CEO) | Option Ex | 16,446 | 6.36 | 104,596 |
| 2015-12-18 | Marken James G. (Vice President, Operations) | Sale | 3,500 | 43.26 | 151,410 |
| 2015-11-12 | Przybyl Arthur (President and CEO) | Buy | 2,500 | 40.95 | 102,375 |
| 2015-09-25 | Arnold Charlotte C. (Vice President and CFO) | Option Ex | 19,060 | 19.68 | 375,100 |
| 2015-09-02 | Arnold Charlotte C. (Vice President and CFO) | Option Ex | 2,106 | 33.00 | 69,498 |
| 2015-08-10 | Przybyl Arthur (President and CEO) | Option Ex | 10,000 | 6.36 | 63,600 |
| 2015-07-17 | Marken James G. (Vice President, Operations) | Option Ex | 7,395 | 6.36 | 47,032 |
| 2015-06-18 | Schrepfer Robert W (VP Bus Dev & Con Mfg) | Option Ex | 9,062 | 6.60 | 59,809 |
| 2015-05-13 | Marken James G. (Vice President, Operations) | Option Ex | 9,020 | 19.68 | 177,513 |
| 2015-05-07 | Przybyl Arthur (President and CEO) | Option Ex | 5,000 | 6.36 | 31,800 |
| 2015-05-06 | Arnold Charlotte C. (VP and CFO) | Option Ex | 4,000 | 6.36 | 25,440 |
| 2015-05-06 | Schrepfer Robert W (VP Bus Dev & Con Mfg) | Option Ex | 2,500 | 6.60 | 16,500 |
| 2015-03-19 | Marken James G. (Vice President, Operations) | Sale | 15,000 | 66.50 | 997,500 |
| 2015-03-12 | Marshbanks Tracy (Director) | Sale | 210,000 | 63.00 | 13,230,000 |
| 2015-03-12 | Arnold Charlotte C. (Vice President and CFO) | Sale | 45,000 | 63.00 | 2,835,000 |
| 2015-03-12 | Przybyl Arthur (President and CEO) | Sale | 75,000 | 63.00 | 4,725,000 |
| 2015-03-12 | Raynor Daniel | Sale | 200,000 | 63.00 | 12,600,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of ANIP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Ani Pharmaceuticals Inc (symbol ANIP, CIK number 1023024) see the Securities and Exchange Commission (SEC) website.